PetMed Express Q1 revenue falls on lower prescription medication sales

PetMed Express

13/08/2026 21:17

Overview
U.S. pet pharmacy's Q1 revenue fell 20% yr/yr on lower prescription medication sales
Net loss narrowed from prior year due to absence of impairment charges
Adjusted EBITDA loss widened to $3.4 mln from $2.7 mln yr/yr

Outlook
Company did not provide specific guidance for future quarters or the full year

Result Drivers
PRESCRIPTION SALES DECLINE - Co said lower prescription medication sales were the main reason for the 20% yr/yr drop in revenue
LOWER MANUFACTURER REBATES - Co said gross profit was hurt by lower manufacturer rebates as a percentage of sales
COST REDUCTIONS - Co said disciplined expense management led to a nearly 14% reduction in general and administrative expenses and a 15% drop in customer acquisition cost

Company press release: ID:nGNX1qWqDv

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
 
$41.01 mln
 
Q1 Loss Per Share
 
$0.28
 
Q1 Net Loss
 
$6.14 mln
 
Q1 Adjusted EBITDA
 
-$3.44 mln
 

Analyst Coverage
The one available analyst rating on the shares is "sell"
The average consensus recommendation for the drug retailers peer group is "buy."
Wall Street's median 12-month price target for PetMed Express, Inc. is $2.15, about 7% above its August 12 closing price of $2.01
The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 32 three months ago

Reuters Recommended Reads
Aug 11 - Canada's Pet Valu Q2 revenue slightly beats on higher retail, franchise sales
Aug 11 - Smithfield Foods trims full-year forecasts as consumers rein in spending
Aug 11 - Canada's Cipher Pharma Q2 revenue falls on lower Natroba sales amid reduced Medicaid coverage

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)